123986-64-1Relevant articles and documents
Supramolecular complexes obtained from porphyrin-crown ether conjugates and a fullerene derivative bearing an ammonium unit
Solladié, Nathalie,Walther, Mathieu E.,Herschbach, Haiko,Leize, Emmanuelle,Dorsselaer, Alain Van,Duarte, Teresa M. Figueira,Nierengarten, Jean-Fran?ois
, p. 1979 - 1987 (2006)
A methanofullerene derivative with an ammonium subunit (1) has been prepared and its ability to form a supramolecular complex with a porphyrin-crown ether conjugate evidenced by NMR, UV-vis, electrospray mass spectrometry (ES-MS) and luminescence experime
Polymer-bound self-folding cavitands
Rafai Far, Adel,Lag Cho, Young,Rang, Alexander,Rudkevich, Dmitry M,Rebek Jr., Julius
, p. 741 - 755 (2002)
The attachment of self-folding cavitands to polymeric supports has been succesfully demonstrated. Crosslinked polystyrene and PEGA were used. The synthesis of cavitands properly functionalized for this purpose is reported. The uptake of quest molecules by the resulting materials and the formation of inclusion complexes on the supports was demonstrated.
CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO
-
Page/Page column 173; 174; 175, (2018/09/19)
The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME
-
Paragraph 0411; 0426; 0427, (2016/12/01)
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.